Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Dec 12, 2025

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 3, 2025

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Dec 1, 2025

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.

Business Wire • Nov 25, 2025

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce FDA approval of POHERDY, the first and only pertuzumab biosimilar in the US, which is interchangeable to Perjeta.

Business Wire • Nov 17, 2025

Organon Analysts Cut Their Forecasts Following Q3 Results

Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.

Benzinga • Nov 11, 2025

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Organon & Co. faces ongoing challenges, with shares down over 75% since debut and recent CEO resignation after inventory probe. OGN Q3 results show stagnant revenues, declining Women's Health sales, and persistent high debt, despite low valuation metrics like a 3.7x forward P/E. Dividend has been slashed, Nexplanon sales fell 50% in the US in Q3, and the company is selling assets to manage leverage and cash flow issues.

Seeking Alpha • Nov 11, 2025

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Organon & Co. ( OGN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Carrie Cox Joseph Morrissey - Interim CEO & Executive VP and Head of Manufacturing & Supply Matthew Walsh - Executive VP & CFO Conference Call Participants Jason Gerberry - BofA Securities, Research Division David Amsellem - Piper Sandler & Co., Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Terence Flynn - Morgan Stanley, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Michael Nedelcovych - TD Cowen, Research Division Presentation Operator Hello, and welcome to the Organon Third Quarter 2025 Earnings Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations.

Seeking Alpha • Nov 10, 2025

Organon Reports Results for the Third Quarter Ended September 30, 2025

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this pivotal time for Organon,” said Joe Morrissey, Organon's Interim Chief Executive Officer. “We are harnessing the company's many strengths, including a diverse portfolio that we expect will generate more than $900 million in free cash flow before one-time costs this year. We also remain committed to.

Business Wire • Nov 10, 2025

Organon (OGN) Q3 Earnings and Revenues Beat Estimates

Organon (OGN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.87 per share a year ago.

Zacks Investment Research • Nov 10, 2025